Treating uterine (endometrial) cancer by targeting DNA damage and replication stress
Targeting Replication Stress and DNA Damage Response in Uterine Cancer
This project develops new treatment approaches that exploit DNA repair weaknesses to help women with advanced or recurrent uterine (endometrial) cancer who need additional options.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11323893 on NIH RePORTER |
What this research studies
Researchers are developing three different ways to attack replication stress and DNA damage response problems that fuel aggressive endometrial cancers, using drug combinations, immune-related strategies, and laboratory models. They will study tumor samples and preclinical models to learn which approaches best kill cancer cells and why some tumors resist treatment. The team at Dana-Farber and Brigham and Women’s will move promising approaches toward early clinical testing and potential salvage therapies for women with advanced or relapsed disease. The work also examines tumor genetics (for example ARID1A and PI3K changes) to help match therapies to patients.
Who could benefit from this research
Good fit: Women with advanced, recurrent, or treatment-resistant endometrial/uterine cancer who have limited standard therapy options would be the ideal candidates.
Not a fit: People with early-stage endometrial cancer successfully treated with surgery alone or individuals with unrelated non-uterine conditions would not be expected to benefit from these approaches.
Why it matters
Potential benefit: If successful, this work could produce new effective salvage therapies for women with advanced or recurrent endometrial cancer and improve survival and treatment options.
How similar studies have performed: Some therapies targeting DNA damage responses have shown promise in other cancer types, but applying and combining these strategies specifically for uterine cancer is relatively new and under active study.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Matulonis, Ursula Anne — Dana-Farber Cancer Inst
- Study coordinator: Matulonis, Ursula Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.